Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27134564 | 0.87 | ALDH1A1 (0.48) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL24073964 | 0.87 | ALDH1A1 (0.39) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL30142823 | 0.85 | ATG4B (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL25063112 | 0.85 | ATG4B (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL27134455 | 0.84 | ALDH1A1 (0.45) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL24073630 | 0.81 | ALDH1A1 (0.41) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL24074165 | 0.80 | ALDH1A1 (0.48) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL24072758 | 0.80 | ALDH1A1 (0.40) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL25063086 | 0.78 | ATG4B (0.54) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL30142728 | 0.78 | ATG4B (0.54) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | ALDH1A1 1427/4885RAB9A 3280/4885NPC1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.